FDA gives green light to Roche cancer test

December 4, 2017

The US Food and Drug Administration has given the green light to Roche for its FoundationOne CDx personalised diagnostic cancer test, the Swiss group said Monday.

Roche said the FDA had approved the test helping doctors understand the genetic profile of patients' tumors to enable better-targeted therapies and clinical tests.

"The approval of FoundationOne CDx represents a major advance in the personalisation of cancer care, facilitating access for patients in the US to a comprehensive pan-tumour companion diagnostic that will help identify approved treatment options based on the molecular footprint of each individual's cancer," said Roche's Chief Medical Officer Sandra Horning, also the firm's head of global product development.

"Our belief is that profiling will increasingly become routine in clinical practice, so we have worked closely with Foundation Medicine to develop an extensive clinically and analytically validated platform that can support both existing and future companion diagnostic needs," Horning said in a statement.

Pharmaceutical companies see development of personally tailored treatment as the way ahead to tackle cancer.

Explore further: FDA approves first-of-a-kind test for cancer gene profiling

Related Stories

FDA approves first-of-a-kind test for cancer gene profiling

December 1, 2017
U.S. regulators have approved a first-of-a-kind test that looks for mutations in hundreds of cancer genes at once, giving a more complete picture of what's driving a patient's tumor and aiding efforts to match treatments ...

Roche breast cancer drug 'helps patients live longer': study

September 29, 2014
A drug developed by Swiss giant Roche to treat an aggressive form of breast cancer has been shown to extend patients' lives by almost 16 months, researchers said Sunday.

Roche taking majority in Foundation Medicine for $1.03B

January 12, 2015
Roche is taking a majority stake in U.S.-based Foundation Medicine in a deal worth $1.03 billion that the Swiss pharmaceutical company says will help it to develop new treatment options for cancer patients.

FDA approves Roche's Avastin for ovarian cancer

November 14, 2014
Swiss drugmaker Roche said Friday that the Food and Drug Administration approved its drug Avastin as a treatment for ovarian cancer.

FDA approves genetic test for lung cancer drug

May 14, 2013
The Food and Drug Administration says it approved a genetic test from Roche to help doctors identify patients who can benefit from a lung cancer drug made by Genentech.

Approval of first HPV test for use with SurePath preservative fluid

July 11, 2016
(HealthDay)—The U.S. Food and Drug Administration has approved Roche's cobas HPV Test as the first diagnostic to be used with cervical cells obtained for a Pap test and collected in SurePath Preservative Fluid.

Recommended for you

Fully reprogrammed virus offers new hope as cancer treatment

May 25, 2018
A cancer treatment that can completely destroy cancer cells without affecting healthy cells could soon be a possibility, thanks to research led by Cardiff University.

Research could help fine-tune cancer treatment

May 25, 2018
Cancer therapies that cut off blood supply to a tumour could be more effective in combination with existing chemotherapeutic drugs—according to new research from the University of East Anglia.

Increasing physical activity linked to better immunity in breast cancer patients, study finds

May 25, 2018
A new study from the University of Toronto's Faculty of Kinesiology & Physical Education has found that moderate to vigorous physical activity may help regulate the levels of C-reactive protein – an important biomarker ...

Study finds gut microbiome can control antitumor immune function in liver

May 24, 2018
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. Their study, published May 25 in Science, was led by researchers in the Center for Cancer Research (CCR) at the National ...

Low-fat diet tied to better breast cancer survival

May 24, 2018
(HealthDay)—Breast cancer patients who adopted a low-fat diet were more likely to survive for at least a decade after diagnosis, compared to patients who ate fattier fare, new research shows.

A cascade of immune processes offers insights to triple-negative breast cancer

May 24, 2018
Cancer is crafty. To survive and thrive, tumors find a way of thwarting our body's natural systems.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.